Best Practice & Research Clinical Rheumatology
Volume 20, Issue 5 , Pages 929-939 , October 2006

Chemokine inhibition in inflammatory arthritis

  • Paul P. Tak, MD, PhD (Professor of Medicine and Director)

      Affiliations

    • Corresponding Author InformationTel.: +31 20 566 2171; Fax: +31 20 691 9658.

References 

  1. Haringman JJ, Tak PP. Chemokine blockade: a new era in the treatment of rheumatoid arthritis?. Arthritis Research and Therapy. 2004;6(3):93–97
  2. Tak PP, Bresnihan B. The pathogenesis and prevention of joint damage in rheumatoid arthritis: advances from synovial biopsy and tissue analysis. Arthritis and Rheumatism. 2000;43(12):2619–2633
  3. Tak PP. Is early rheumatoid arthritis the same disease process as late rheumatoid arthritis?. Best Practice & Research: Clinical Rheumatology. 2001;15(1):17–26
  4. Buckley CD. Michael Mason prize essay 2003. Why do leucocytes accumulate within chronically inflamed joints?. Rheumatology (Oxford). 2003;42(12):1433–1444
  5. Buckley CD. Why does chronic inflammatory joint disease persist?. Clinical Medicine. 2003;3(4):361–366
  6. Haringman JJ, Oostendorp RL, Tak PP. Targeting cellular adhesion molecules, chemokines and chemokine receptors in rheumatoid arthritis. Expert Opinion on Emerging Drugs. 2005;10(2):299–310
  7. Szekanecz Z, Szucs G, Szanto S, et al. Chemokines in rheumatic diseases. Current Drug Targets. 2006;7(1):91–102
  8. Tarrant TK, Patel DD. Chemokines and leukocyte trafficking in rheumatoid arthritis. Pathophysiology. 2006;13(1):1–14
  9. Rudolph EH, Woods JM. Chemokine expression and regulation of angiogenesis in rheumatoid arthritis. Current Pharmaceutical Design. 2005;11(5):613–631
  10. Haringman JJ, Ludikhuize J, Tak PP. Chemokines in joint disease: the key to inflammation?. Annals of the Rheumatic Diseases. 2004;63(10):1186–1194
  11. Koch AE. Chemokines and their receptors in rheumatoid arthritis: future targets?. Arthritis and Rheumatism. 2005;52(3):710–721
  12. Vergunst CE, Tak PP. Chemokines: their role in rheumatoid arthritis. Current Rheumatology Reports. 2005;7(5):382–388
  13. Charo IF, Ransohoff RM. The many roles of chemokines and chemokine receptors in inflammation. New England Journal of Medicine. 2006;354(6):610–621
  14. Mackay CR. Chemokines: immunology's high impact factors. Nature Immunology. 2001;2(2):95–101
  15. Qu ZH, Garcia CH, O'Rourke LM, et al. Local proliferation of fibroblast-like synoviocytes contributes to synovial hyperplasia – results of proliferation cell nuclear antigen/cyclin, C-myc, and nucleolar organizer region staining. Arthritis and Rheumatism. 1994;37:212–220
  16. Endo H, Akahoshi T, Takagishi K, et al. Elevation of interleukin-8 (IL-8) levels in joint fluids of patients with rheumatoid arthritis and the induction by IL-8 of leukocyte infiltration and synovitis in rabbit joints. Lymphokine and Cytokine Research. 1991;10(4):245–252
  17. Deleuran B, Lemche P, Kristensen M, et al. Localisation of interleukin 8 in the synovial membrane, cartilage-pannus junction and chondrocytes in rheumatoid arthritis. Scandinavian Journal of Rheumatology. 1994;23(1):2–7
  18. Kraan MC, Patel DD, Haringman JJ, et al. The development of clinical signs of rheumatoid synovial inflammation is associated with increased synthesis of the chemokine CXCL8 (interleukin-8). Arthritis Research. 2001;3(1):65–71
  19. Koch AE, Kunkel SL, Harlow LA, et al. Enhanced production of monocyte chemoattractant protein-1 in rheumatoid arthritis. The Journal of Clinical Investigation. 1992;90(3):772–779
  20. Luster AD. Chemokines – chemotactic cytokines that mediate inflammation. New England Journal of Medicine. 1998;338(7):436–445
  21. Haringman JJ, Smeets TJ, Reinders-Blankert P, et al. Chemokine and chemokine receptor expression in paired peripheral blood mononuclear cells and synovial tissue of patients with rheumatoid arthritis, osteoarthritis, and reactive arthritis. Annals of the Rheumatic Diseases. 2006;65(3):294–300
  22. Weber C, Weber KS, Klier C, et al. Specialized roles of the chemokine receptors CCR1 and CCR5 in the recruitment of monocytes and T(H)1-like/CD45RO(+) T cells. Blood. 2001;97(4):1144–1146
  23. Tak PP, Smeets TJM, Daha MR, et al. Analysis of the synovial cellular infiltrate in early rheumatoid synovial tissue in relation to local disease activity. Arthritis and Rheumatism. 1997;40:217–225
  24. Takemura S, Braun A, Crowson C, et al. Lymphoid neogenesis in rheumatoid synovitis. Journal of Immunology. 2001;167(2):1072–1080
  25. Manzo A, Paoletti S, Carulli M, et al. Systematic microanatomical analysis of CXCL13 and CCL21 in situ production and progressive lymphoid organization in rheumatoid synovitis. European Journal of Immunology. 2005;35(5):1347–1359
  26. Shi K, Hayashida K, Kaneko M, et al. Lymphoid chemokine B cell-attracting chemokine-1 (CXCL13) is expressed in germinal center of ectopic lymphoid follicles within the synovium of chronic arthritis patients. Journal of Immunology. 2001;166(1):650–655
  27. Carlsen HS, Baekkevold ES, Morton HC, et al. Monocyte-like and mature macrophages produce CXCL13 (B cell-attracting chemokine 1) in inflammatory lesions with lymphoid neogenesis. Blood. 2004;104(10):3021–3027
  28. Qin S, Rottman JB, Myers P, et al. The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions. The Journal of Clinical Investigation. 1998;101(4):746–754
  29. Burman A, Haworth O, Hardie DL, et al. A chemokine-dependent stromal induction mechanism for aberrant lymphocyte accumulation and compromised lymphatic return in rheumatoid arthritis. Journal of Immunology. 2005;174(3):1693–1700
  30. Vergunst CE, van de Sande MG, Lebre MC, et al. The role of chemokines in rheumatoid arthritis and osteoarthritis. Scandinavian Journal of Rheumatology. 2005;34(6):415–425
  31. Harada A, Sekido N, Akahoshi T, et al. Essential involvement of interleukin-8 (IL-8) in acute inflammation. Journal of Leukocyte Biology. 1994;56(5):559–564
  32. Ogata H, Takeya M, Yoshimura T, et al. The role of monocyte chemoattractant protein-1 (MCP-1) in the pathogenesis of collagen-induced arthritis in rats. Journal of Pathology. 1997;182(1):106–114
  33. Gong JH, Ratkay LG, Waterfield JD, et al. An antagonist of monocyte chemoattractant protein 1 (MCP-1) inhibits arthritis in the MRL-lpr mouse model. The Journal of Experimental Medicine. 1997;186(1):131–137
  34. Matthys P, Hatse S, Vermeire K, et al. AMD3100, a potent and specific antagonist of the stromal cell-derived factor-1 chemokine receptor CXCR4, inhibits autoimmune joint inflammation in IFN-gamma receptor-deficient mice. Journal of Immunology. 2001;167(8):4686–4692
  35. Yang YF, Mukai T, Gao P, et al. A non-peptide CCR5 antagonist inhibits collagen-induced arthritis by modulating T cell migration without affecting anti-collagen T cell responses. European Journal of Immunology. 2002;32(8):2124–2132
  36. Vierboom MP, Zavodny PJ, Chou CC, et al. Inhibition of the development of collagen-induced arthritis in rhesus monkeys by a small molecular weight antagonist of CCR5. Arthritis and Rheumatism. 2005;52(2):627–636
  37. Shahrara S, Proudfoot AE, Woods JM, et al. Amelioration of rat adjuvant-induced arthritis by Met-RANTES. Arthritis and Rheumatism. 2005;52(6):1907–1919
  38. Bruhl H, Cihak J, Schneider MA, et al. Dual role of CCR2 during initiation and progression of collagen-induced arthritis: evidence for regulatory activity of CCR2+ T cells. Journal of Immunology. 2004;172(2):890–898
  39. Quinones MP, Ahuja SK, Jimenez F, et al. Experimental arthritis in CC chemokine receptor 2-null mice closely mimics severe human rheumatoid arthritis. The Journal of Clinical Investigation. 2004;113(6):856–866
  40. Fife BT, Huffnagle GB, Kuziel WA, et al. CC chemokine receptor 2 is critical for induction of experimental autoimmune encephalomyelitis. The Journal of Experimental Medicine. 2000;192(6):899–905
  41. Boring L, Gosling J, Cleary M, Charo IF. Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature. 1998;394(6696):894–897
  42. Belperio JA, Keane MP, Burdick MD, et al. Critical role for the chemokine MCP-1/CCR2 in the pathogenesis of bronchiolitis obliterans syndrome. The Journal of Clinical Investigation. 2001;108(4):547–556
  43. Bird JE, Giancarli MR, Kurihara T, et al. Increased severity of glomerulonephritis in C-C chemokine receptor 2 knockout mice. Kidney International. 2000;57(1):129–136
  44. Blease K, Mehrad B, Standiford TJ, et al. Enhanced pulmonary allergic responses to Aspergillus in CCR2-/- mice. Journal of Immunology. 2000;165(5):2603–2611
  45. Hogaboam CM, Bone-Larson CL, Steinhauser ML, et al. Exaggerated hepatic injury due to acetaminophen challenge in mice lacking C-C chemokine receptor 2. American Journal of Pathology. 2000;156(4):1245–1252
  46. Haringman JJ, Gerlag DM, Smeets TJM et al. A randomized controlled trial with an anti-CCL2 (MCP-1) monocloncal antibody in patients with rheumatoid arthritis. Arthritis and Rheumatism 2006 [in press].
  47. Haringman JJ, Kraan MC, Smeets TJ, et al. Chemokine blockade and chronic inflammatory disease: proof of concept in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases. 2003;62(8):715–721
  48. Katschke KJ, Rottman JB, Ruth JH, et al. Differential expression of chemokine receptors on peripheral blood, synovial fluid, and synovial tissue monocytes/macrophages in rheumatoid arthritis. Arthritis and Rheumatism. 2001;44(5):1022–1032
  49. Gladue RP, Tylaska LA, Brissette WH, et al. CP-481,715, a potent and selective CCR1 antagonist with potential therapeutic implications for inflammatory diseases. The Journal of Biological Chemistry. 2003;278(42):40473–40480
  50. Ho CY, Wong CK, Li EK, et al. Suppressive effect of combination treatment of leflunomide and methotrexate on chemokine expression in patients with rheumatoid arthritis. Clinical and Experimental Immunology. 2003;133(1):132–138
  51. van den Brink HR, van Wijk MJ, Geertzen RG, et al. Influence of corticosteroid pulse therapy on the serum levels of soluble interleukin 2 receptor, interleukin 6 and interleukin 8 in patients with rheumatoid arthritis. The Journal of Rheumatology. 1994;21(3):430–434
  52. Taylor PC, Peters AM, Paleolog E, et al. Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor alpha blockade in patients with rheumatoid arthritis. Arthritis and Rheumatism. 2000;43(1):38–47
  53. Tak PP. Effects of infliximab treatment on rheumatoid synovial tissue. The Journal of Rheumatology. Supplement. 2005;74:31–34
  54. Hendrix CW, Collier AC, Lederman MM, et al. Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection. Journal of Acquired Immune Deficiency Syndromes. 2004;37(2):1253–1262
  55. Liang M, Rosser M, Ng HP, et al. Species selectivity of a small molecule antagonist for the CCR1 chemokine receptor. European Journal of Pharmacology. 2000;389(1):41–49
  56. Xanthou G, Duchesnes CE, Williams TJ, et al. CCR3 functional responses are regulated by both CXCR3 and its ligands CXCL9, CXCL10 and CXCL11. European Journal of Immunology. 2003;33(8):2241–2250
  57. Overall CM, McQuibban GA, Clark-Lewis I. Discovery of chemokine substrates for matrix metalloproteinases by exosite scanning: a new tool for degradomics. Biological Chemistry. 2002;383(7-8):1059–1066
  58. Carter PH. Chemokine receptor antagonism as an approach to anti-inflammatory therapy: ‘just right’ or plain wrong?. Current Opinion in Chemical Biology. 2002;6(4):510–525
  59. Klein B, Wijdenes J, Zhang XG, et al. Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia. Blood. 1991;78(5):1198–1204
  60. Liu ET, Karuturi KR. Microarrays and clinical investigations. New England Journal of Medicine. 2004;350(16):1595–1597
  61. Gerlag DM, Haringman JJ, Smeets TJ, et al. Effects of oral prednisolone on biomarkers in synovial tissue and clinical improvement in rheumatoid arthritis. Arthritis and Rheumatism. 2004;50(12):3783–3791
  62. Haringman JJ, Gerlag DM, Zwinderman AH, et al. Synovial tissue macrophages: a sensitive biomarker for response to treatment in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases. 2005;64(6):834–838

PII: S1521-6942(06)00073-8

doi: 10.1016/j.berh.2006.06.001

Best Practice & Research Clinical Rheumatology
Volume 20, Issue 5 , Pages 929-939 , October 2006

Article Tools